O.L. CHERNOVA, E.S. MILYTINA

Interregional Clinical and Diagnostic Center, 12a Karbyshev Str., 420101 Kazan, Russian Federation

 Chernova O.L. — cardiologist of a polyclinic, e-mail: olgaleon07@rambler.ru

Milyutina E.S. — Head of the Polyclinic Department, tel. (843) 291-11-23, e-mail: milyoutina.69@mail.ru

 Today in the world there is a pandemic of HIV infection, the incidence of the world population is steadily growing. The patients infected with HIV have an increased risk and incidence of cardiovascular disease, the appearance of which is associated with a significant deterioration in the prognosis. Thus, pulmonary hypertension is an independent predictor of death in patients with HIV infection. The article reviews and analyzes available literature data on the development of cardiovascular diseases in HIV-infected patients, examines in detail the epidemiology and pathogenesis of the development of cardiovascular complications associated with HIV infection, in particular, pulmonary arterial hypertension, the features of its diagnosis and treatment of this category of patients.

Key words: HIV-infection, HIV-associated diseases, pulmonary arterial hypertension

(For citation: Chernova O.L., Milyutina E.S. Pulmonary arterial hypertension as one of variants of heart-vascular diseases associated with HIV-infection. Practical Medicine. 2018)

REFERENCES

1. Spravka VICH-infektsiya v Rossiyskoy Federatsii na 31 dekabrya 2016 g. [Help HIV-infection in the Russian Federation on December 31, 2016]. Federalʹnyy nauchno-metodicheskiy tsentr po profilaktike i borʹbe so SPIDom FBUN Tsentralʹnogo NII ehpidemiologii.
2. Spravka VICH-infektsiya v Rossiyskoy Federatsii v 2017 g. [Help HIV-infection in the Russian Federation in 2017]. Federalʹnyy nauchno-metodicheskiy tsentr po profilaktike i borʹbe so SPIDom FBUN Tsentralʹnogo NII ehpidemiologii Rospotrebnadzora.
3. Gusev D.A., Buzunova S.A., Yakovlev A.A. et al. Concomitant diseases and risk factors for their development in HIV-infected patients over 40 years old. Zhurnal infektologii, 2017, vol. 9, no. 3, pp. 40–45 (in Russ.).
4. VICH-infektsiya, vtorichnye i soputstvuyushchie zabolevaniya [HIV infection, secondary and associated diseases]. Tematicheskiy arkhiv Baltiyskogo meditsinskogo obrazovatelʹnogo tsentra po materialam zhurnalov: “VICH-infektsiya i immunosupressii”, “Luchevaya diagnostika i terapiya”, “Meditsinskiy akademicheskiy zhurnal”. Saint Petersburg: Baltiyskiy med. obrazovatelʹnyy tsentr, 2014, no. 8. P. 131.
5. Sabin C.A., Worm S.W. et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, 2008, vol. 371, pp. 1417–1426.
6. Esser S., Gelbrich G., Brockmeyer N. et al. Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clinical Research in Cardiology, 2013, vol. 102 (3), rr. 203–213.
7. Purnell J.Q., Zambon A., Knopp R.H. et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS, 2000, vol. 14, rr. 51–57.
8. Hui D.Y. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res, 2003, vol. 42, no. 2, rr. 81–92.
9. Triant V.A. HIV and Cardiovascular Disease. HIV/AIDS Annual Update, 2010.
10. Vatier C., Leroyer S., Quette J. et al. HIV protease inhibitors differently affect human subcutaneos and visceral fat: they induce IL — 6 production and alter lipid storage capacity in subcutaneous but not visceral adipose tissue explants. Antiviral Therapy, 2008, vol. 13, no. 4.
11. Miller T.L., Borkowsky W., Di Meglio L.A. et al. Metabolic Abnormalities and Viral Replication is Associated with Biomarkers of Vascular Dysfunction in HIVInfected Children. HIV Med, 2012, vol.13, no. 5, rr. 264–275.
12. Subramanian S., Tawakol A., Burdo T.H. et al. Arterial Inflammation in Patients with HIV. JAMA, 2012, vol. 308, no. 4, rr. 379–386.
13. Komarova I.V. Serdechno-sosudistyy risk u VICH-infitsirovannykh patsientov: avtoref. dis. … kand. med. nauk [Cardiovascular risk in HIV-infected patients. Synopsis of dis. PhD med. sciences]. Moscow, 2014. 24 p.
14. Mu H., Chai H., Lin P.H. et al. Current update on HIV-associated vascular disease and endothelial dysfunction. World Journal Surgery, 2007, vol. 31, no. 4, rr. 632–643.
15. Bernardino J., Merino J., Serrano L. et al. Longitudinal comparison of inflammatory, coagulation and metabolic biomarkers in patients who start ART versus patients who remain ART-naı¨ve. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection. Journal of the International AIDS Society, 2012, vol.15, no. 4, rr.182–184.
16. Arildsen H., Sørensen K.E., Ingerslev J.M. et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients 142 improve after initiation of highly active antiretroviral therapy. HIV Med, 2013, vol. 14, no. 1, rr. 1–9.
17. Baker J., Ayenew W., Quick H. et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. Journal Infectious Disease, 2010, vol. 201, rr. 285–292.
18. Abdollahi A., Shoar T.S. Hyperhomocysteinemia in HIV-Infected Individuals: Correlation of a Frequent Prothrombotic Factor with CD4+ Cell Count. Oman Med Journal, 2012, vol. 27, no. 3, rr. 224–227.
19. Chazova I.E. Martynyuk T.V., Avdeev S.N., Arutyunov G.P., Volkov A.V., Nakonechnikov S.N., Privalova E.V. Diagnosis and treatment of pulmonary hypertension. Russian recommendations. Kardiovaskulyarnaya terapiya i profilaktika, 2007, no. 6 (in Russ.).
20. Legochnaya gipertenziya, pod red. Chazovoy I.E. i Martynyuk T.V. [Pulmonary hypertension. Ed. by Chazova I.E. and Martynyuk T.V.]. Moscow: Praktika, 2015. Pp. 467–478.
21. Yakushin S.S., Filippov E.V. HIV infection and cardiovascular complications . Klinitsist, 2011, no. 2, pp. 6–12 (in Russ.).
22. Saidi A., Bricker J.T. Pulmonary hypertension in patients infected with HIV. Cardiology in AIDS. Lipshultz S.E. ed. NY: Chapman & Hall. 1998. Rr. 255–63.
23. Chazova I.E., Avdeev S.N., Tsareva N.A. et al. Clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Terapevticheskiy Arkhiv, 2014, no. 9, pp. 4–23 (in Russ.).
24. Mette S.A., Palevsky H.I., Pietra G.G. et al. Primary pulmonary hypertension in association with human immunodeficiency virus infectiion. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. The American Review of Respiratory Disease, 1992, vol. 145, rr. 1196–1200.
25. Pellictlli A.M., Palmieri F., Cicalini et al. Pathogenesis of HIV-related pulmonary hypertension. Annals of the New York Academy of Sciences, 2001, vol. 946, rr. 82–94.
26. Dorfmller P., Perros F., Balabanian K. et al. Inflammation in pulmonary arterial hypertension. The European Respiratory Journal, 2003, vol. 22, rr. 358–363.
27. Simonneau G., Gatzoulis M.A., Ian Adatia I.,et al. Update Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, vol. 62, no. 25, rr. 34–41.
28. Parikh R.V., Scherzer R., Nitta E.M. et al. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. AIDS, 2014, vol. 28, I. 4, rr. 511–519.
29. Degano B., Guillaume M., Savale L. et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS, 2010, vol. 24, pp. 67–75.
30. Zuber J.P., Calmy A., Evison J.M. et al. Swiss HIV Cohort Study Group Pulmonary arterial hypertension related to HIV-infection: improved hemodynamics and survival associated with antiretriviral therapy. Clinical Infectious Diseases, 2004, vol. 38, pp. 1178–1185.
31. Petitpretz P., Brenot F., Azarian R. et al. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation, 1994, vol. 89, pp. 2722–2727.
32. Sitbon O., Gressin V., Speich R. et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, vol.170, pp. 1212–1217.
33. Ghofrany H.A., Friese G., Discher T. et al. Inhaled iloprost is a potent acute pulmonary vasodilatator in HIV-related severe pulmonary hypertension. Europear Respiratory Journal, 2004, vol. 23, pp. 321–326.